Jiangxi Bio has been recognized on the provincial lists of “Little Lighthouse” enterprises and “Advanced-Level Smart Factories,” with digital and intelligent technologies accelerating and empowering the high-quality development of antiserum production.

Recently, the Jiangxi Provincial Department of Industry and Information Technology announced the third batch of provincial-level… “ Little Lighthouse ” List of enterprises, 2026 The annual list of provincial “Advanced-Level Smart Factories.” Jiangxi Institute of Biological Products Co., Ltd. (hereinafter referred to as… “ Jiangxi Biology ” or “ Company ” ) Thanks to its deeply developed digital ecosystem, it has been awarded " Little Lighthouse " The company’s attainment of two provincial-level designations—“Advanced-Level Smart Factory”—marks a solid step forward in Jiangxi Bio’s journey to lead the upgrade of the antiserum industry through digital and intelligent transformation, thereby driving high-quality development in the biopharmaceutical sector.

Figure: Jiangxi Provincial Department of Industry and Information Technology’s “Notice on the Third Batch of Jiangxi Province” “ Little Lighthouse ” “Public Notice of the List of Enterprises,” “Regarding” 2026 Public Notice of the List of Advanced-Level Smart Factories in Jiangxi Province for the Year 

Strengthen the digital infrastructure and establish a benchmark for advanced intelligent manufacturing. 

Over the years, Jiangxi Bio has been actively promoting the deep integration of digitalization, intelligent technologies, and the entire anti-serum industry chain, leveraging… “ Research and development - Production - Sales ” Its three‑in‑one integrated connectivity platform builds a smart manufacturing system that spans the entire value chain, firmly establishing a digital foundation and enabling end-to-end, full‑chain digitalization to drive efficiency gains. 

As of now, Jiangxi Bio has independently established “ Jiang Sheng · Industrial Internet Platform ” , while achieving integrated digital management of the company’s research and production processes, it has also established China’s first facility employing isolator-based aseptic filling technology. GMP A state-of-the-art biopharmaceutical manufacturing facility for human use, significantly enhancing product quality, stability, and safety. 

toward “ Digital intelligence ” Step forward   Empowering the commercialization of biological research outcomes in Jiangxi Province 

As one of the few domestic and global companies to achieve end-to-end integration across the entire antibody‑serum value chain, Jiangxi Bio is committed to continuously optimizing and innovating its animal immunization and antibody‑serum production processes, while steadily increasing its investment in research and development and technological innovation. 

2025 In [year], the company successfully obtained two approvals from the National Medical Products Administration ( NMPA ) The product approval numbers issued are for two new specifications of human tetanus antitoxin ( TAT ). This new product is China’s first and only marketed human vaccine packaged in preservative-free vials and inactivated with the peste des petits ruminants virus. TAT , the product has effectively reduced the adverse reaction rate to 0.03% , significantly below the industry average, thereby providing clinicians with a safer and higher‑quality prevention and treatment solution. In the same year, the company successively obtained clinical approval for both antiviper venom serum and anticobra venom serum, demonstrating remarkable results from the integration of digital intelligence and innovative R&D. 

In addition, the company has built Jiangxi Province’s first pilot-scale platform for biotherapeutic antibody drugs, integrating digital technologies throughout the entire technology-transfer process. This approach effectively simulates real-world production conditions, reducing the R&D cycle by nearly… on average. 40% Recently, the company published in an international journal a synergistic dual-enzyme “one-pot” method that, through its molecular mechanism, is advancing the production of equine antiserum toward higher purity and greater potency. At the same time, the company is actively adopting digital twin technology to build… " Visible, Optimizable, Predictable " Our intelligent R&D system continuously advances the integration of cutting-edge purification processes and the exploration of frontier technologies, leveraging technological innovation to consistently enhance production-line quality while reducing costs and improving efficiency. 

The management of Jiangxi Bio stated that , this time selected at the provincial level " Little Lighthouse " The designation of the company as a provincial-level advanced smart factory not only fully recognizes the phased achievements of Jiangxi Bio’s digital and intelligent transformation but also serves as a powerful incentive for the company to continue deepening this transformation. Looking ahead, Jiangxi Bio will further deepen the integration of digital and intelligent technologies, continuously fostering the seamless convergence of smart manufacturing with scientific research innovation and industrial efficiency enhancement, thereby achieving “R&D… - produce - “Xiao” achieves cost reduction and efficiency gains across three platforms, with product quality steadily improving, delivering products that are safer, more effective, and of higher quality. “ China Antiserum Program ” Contribute to the global public health cause. 

-  Finished -

Regarding Jiangxi Institute of Biological Products Co., Ltd. 

Jiangxi Institute of Biological Products Co., Ltd. is a leading enterprise in China’s antiserum industry and a national high-tech company, with its history dating back to… 1969 The Jiangxi Branch of the Shanghai Institute of Biological Products, established in [year], is one of the few companies worldwide to have achieved full‑chain integration in the production of antiserums. The company adheres to… “ Providing high-quality medicines for people around the world. ” With a strong sense of mission and responsibility, the company has deeply cultivated four core areas—viral infections, bacterial and bacterial toxin‑induced infections, biotoxin poisoning, and autoimmune diseases—aiming to establish a global hub for antiserum products. To date, its products have been exported to markets around the world. 30 In more than [number] countries and regions, we have served over one billion patients worldwide, continuously contributing China’s strength to global public health. For more information, please visit: https://www.jxswzp.cn/ 。